Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunoPrecise Antibodies Ltd. - Common Stock (NQ:IPA)

1.310 +0.250 (+23.58%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ImmunoPrecise Antibodies Ltd. - Common Stock

< Previous 1 2 3 4 5 Next >
ImmunoPrecise Antibodies Welcomes Mitch Levine To Its Board Of Directors, To Announce Quarterly Results On December 14
Via ACCESSWIRE
IPA Announces Pricing of $1.1 Million Public Offering of Common Shares
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA Announces Proposed Public Offering of Common Shares
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise’s BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery
Via ACCESSWIRE
BioStrand® Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA’s Subsidiary, BioStrand, Provides an Update on LENSai™
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA Provides Update on Growth Strategy and Recent Share Price Movement
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Overcoming the Information Integration Dilemma: Revolutionizing The Fusion Of Complex Biological Data
Via ACCESSWIRE
How ImmunoPrecise Antibodies Is Leveraging AI To Revolutionize Antibody Research
Via ACCESSWIRE
ImmunoPrecise Antibodies Announces CFO Transition
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA Announces Board Refreshment
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA Responds to 13D Filing
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies Invites Investors and Stakeholders to Exclusive Interview with Market Radius Research
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2023 on July 7th, 2023.
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
“Convergence of AI and Biology: Companies at the Forefront of Transformative Innovations”:- IPA, MRKR, PRAX , RMED
Via AB Newswire
Topics Artificial Intelligence
IPA’s Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID)
From ImmunoPrecise Antibodies
Via Business Wire
Healthcare and AI “Paradigm Shift” Stocks in Focus: IPA, MGRX, INBS, RMED
Via AB Newswire
Topics Artificial Intelligence
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) Is Strategically Built To Advance The Future
Via AB Newswire
Topics Artificial Intelligence
IPA Releases New HYFT-Powered In Silico Humanization Platform, Aims to Disrupt the Transgenic Animal Model Market
From ImmunoPrecise Antibodies
Via Business Wire
IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology
From ImmunoPrecise Antibodies
Via Business Wire
IPA to Present at Jefferies Healthcare Conference 2023
From ImmunoPrecise Antibodies
Via Business Wire
The Street Reports: NASDAQ Stocks Poised to Disrupt the Markets: IPA, RELI, SKYX, AZ
Via AB Newswire
Topics Artificial Intelligence
TheStreetReports: AI Biotech Stocks to Watch 2023: IPA, ONTX, AGEN, PBIO
Via AB Newswire
Topics Artificial Intelligence
ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas
From ImmunoPrecise Antibodies
Via Business Wire
European Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® Technology
From ImmunoPrecise Antibodies
Via Business Wire
ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates
From ImmunoPrecise Antibodies
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.